MPL and autoimmune thrombocytopenic purpura: Fostamatinib was approved by FDA in April 2018 to treat chronic and refractory immune thrombocytopenia in patients who have had insufficient response to previous treatment including corticosteroids, immunoglobulins, splenectomy, and/or a TPO-R agonist [59,60].